Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Aug
17
UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters
May
23
UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022
May
23
First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022
May
10
Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association
May
10
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
Mar
28
FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)
Mar
26
New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting
Mar
07
UCB Completes Acquisition of Zogenix, Inc.
Feb
04
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results